CN102321015A - Method for preparing key intermediate 2-(cyclopropylamido)-3-pyridine formic acid of anti-aids medicament Nevirapine - Google Patents

Method for preparing key intermediate 2-(cyclopropylamido)-3-pyridine formic acid of anti-aids medicament Nevirapine Download PDF

Info

Publication number
CN102321015A
CN102321015A CN201110180511A CN201110180511A CN102321015A CN 102321015 A CN102321015 A CN 102321015A CN 201110180511 A CN201110180511 A CN 201110180511A CN 201110180511 A CN201110180511 A CN 201110180511A CN 102321015 A CN102321015 A CN 102321015A
Authority
CN
China
Prior art keywords
nevirapine
key intermediate
cyclopropyl amino
carboxylic acid
pyridine carboxylic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201110180511A
Other languages
Chinese (zh)
Inventor
王德峰
王炳才
祝海峰
朱小飞
俞健钧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JIANGSU DEFENG PHARMACEUTICAL CO Ltd
Original Assignee
JIANGSU DEFENG PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JIANGSU DEFENG PHARMACEUTICAL CO Ltd filed Critical JIANGSU DEFENG PHARMACEUTICAL CO Ltd
Priority to CN201110180511A priority Critical patent/CN102321015A/en
Publication of CN102321015A publication Critical patent/CN102321015A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a method for preparing a key intermediate 2-(cyclopropylamido)-3-pyridine formic acid of an anti-aids medicament Nevirapine. The synthesis method comprises the following steps of: reacting 2-amido3-cyanopyridine with chlorinated cyclopropan (or cyclopropyl bromide) to generate 2-(cyclopropylamido)-3-cyanopyridine; and hydrolyzing in alkali to generate 2-(cyclopropylamido)-3-pyridine formic acid. The invention has the advantages of simple process, easiness in operation and high product yield, and the product purity is larger than 99 percent.

Description

The preparation method of a kind of anti-AIDS drug nevirapine key intermediate 2-(cyclopropyl amino)-3-pyridine carboxylic acid
Technical field
The present invention relates to the compound method of a kind of anti-AIDS drug nevirapine key intermediate 2-(cyclopropyl amino)-3-pyridine carboxylic acid, belong to organic chemistry and technical field of medicine synthesis.
Background technology
2-(cyclopropyl amino)-3-pyridine carboxylic acid is anti-AIDS drug nevirapine (Nevirapine) key intermediate, and nevirapine has another name called the happy life of dimension (Viramune), chemical structural formula:
Figure 947303DEST_PATH_IMAGE001
Chemical structure names: 11-cyclopropyl-5,11-dihydro-4-methyl-6 hydrogen-two pyridines-[3,2-b:2,3-e] [1,4] diazepine-6-ketone, molecular formula is C15H14N4O, molecular weight is 266.3.Nevirapine be the sweet type RTI of the non-nuclear of HIV-1 (Non-Nucleoside Reverse Transcriptase Inhibitor, NNRTI).Nevirapine directly is connected with the reversed transcriptive enzyme of HIV-1 and breaks through the catalysis end that makes this enzyme to be blocked RNA and relies on the dna polymerase activity with the DNA dependence.
In carinogenicity research, nevirapine increases the incidence of the liver tumor of mouse (dosage reached for 750 mg/kg/ days) and rat (dosage reached for 35 mg/kg/ days).But these discoveries are that a more obstinate liver enzyme inducer is relevant with nevirapine probably, but can not produce genotoxicity.In following a series of bodies and in the analysis of the toxicity of in vitro tests gene, nevirapine does not demonstrate the activity of transgenation or mutagenesis.These tests comprise: (Ames: salmonella strain and Escherichia coli), mammalian cell gene mutation evaluation (CHO/HGPRT) are measured in the microbial gene sudden change, oral medication Hou utilizes the Chinese hamster ovary line cell to carry out methods such as science of heredity mensuration and the evaluation of mouse bone marrow cells micronucleus.In reproductive toxicity studies, the data suggest that in female rats receiving nevirapine to song XIAN as measured by the area under the dose to achieve full identity cloth, their fertility is compromised.This dosage is suitable with the recommended dose of this medicinal what human body.
The main method of at present synthetic this midbody is Boswell, Robert Frederick; Gupton, Bernard Franklin; Lo; The patented process of Young Sek US 20040002603; Mainly be to close at solvent from 2-chloro-3-cyanopyridine and cyclopropylamine that reaction obtains 2-(cyclopropyl amino)-3-cyanopyridine under the acid binding agent condition, obtain 2-(cyclopropyl amino)-3-pyridine carboxylic acid through hydrolysis again.
Summary of the invention
The object of the present invention is to provide a kind of technology simple, the synthetic 5-halogen 2-(cyclopropyl amino) of the different process route that yield is high-3-pyridine carboxylic acid method.
Technical solution of the present invention is: the preparation method of a kind of anti-AIDS drug nevirapine key intermediate 2-(cyclopropyl amino)-3-pyridine carboxylic acid is characterized in that: be made up of following 2 steps reaction:
Amino 3-cyanopyridine of the first step: 2-and halo Trimetylene react in the presence of solvent and acid binding agent and obtain 2-(cyclopropyl amino)-3-cyanopyridine.
Second step: the hydrolysis under alkaline condition of 2-(cyclopropyl amino)-3-cyanopyridine obtains nevirapine key intermediate 2-(cyclopropyl amino)-3-pyridine carboxylic acid.
Further, in the first step, said halo Trimetylene is meant chloro Trimetylene or cyclopropane bromide, and said solvent is meant the mixing solutions of water, alcohol or water and alcohol.
Further, said alcohol is that carbon 1 is to carbon 6 alcohol, terepthaloyl moietie, propandiols material.
Further, in the first step, said acid binding agent is meant triethylamine, diethylamine, ethamine class amine salt and salt of wormwood, yellow soda ash class carbonate.
Further, the temperature of reaction in the first step is 10~100 degree; The amino 3-cyanopyridine of 2-: halo Trimetylene: acid binding agent: solvent (mol ratio)=1:0.2~5:0.2~5:1~100.
Further, said hydrolysis is under the condition of alkaline condition sodium hydroxide or Pottasium Hydroxide existence, to react.
The invention has the advantages that: technology is simple, and is easy to operate, and product yield is high.
Below in conjunction with embodiment the present invention is described further:
Embodiment:
Reaction of the present invention is specific as follows:
Generate 2-(cyclopropyl amino)-3-cyanopyridine by amino 3-cyanopyridine of 2-and chloro Trimetylene (or cyclopropane bromide reaction), generate 2-(cyclopropyl amino)-3-pyridine carboxylic acid through basic hydrolysis again, reaction formula is following:
Figure 523778DEST_PATH_IMAGE002
be X=Cl or Br wherein.
The amino 3-cyanopyridine of 2-: halo Trimetylene: acid binding agent: react under 10-100 degree condition up to transforming fully solvent (mol ratio)=1:0.2~5:0.2~5:1~100; The pressure reducing and steaming solvent adds entry; Be cooled to-5 to 30 degree, agitation and filtration obtains product 2-(cyclopropyl amino)-3-cyanopyridine; Then with 2-(cyclopropyl amino)-3-cyanopyridine in doubly hydrolysis in sodium hydroxide or the potassium hydroxide solution of mole of 1-6, add water after boiling off solvent, transfer PH to acid, filter and obtain product.
Embodiment 1:
In there-necked flask, add 120 amino-3 cyanopyridines of gram 2-and 140 milliliters of ethanol, add 138 gram salt of wormwood and 200 ml waters under stirring; Slowly add the chloro Trimetylene of 80 grams again, added afterreaction 24 hours, HPLC analyzes up to reacting completely; The pressure reducing and steaming solvent adds 400 ml waters; Be cooled to the 0-5 degree, filter and obtain 115 gram products, content is more than 98.0%.
Embodiment 2:
In there-necked flask, add 120 amino-3 cyanopyridines of gram 2-and 140 milliliters of ethanol, add 220 gram triethylamines under stirring; Slowly add the chloro Trimetylene of 80 grams again, added afterreaction 24 hours, HPLC analyzes up to reacting completely; The pressure reducing and steaming solvent adds 300 ml waters; Be cooled to the 0-5 degree, filter and obtain 140 gram products, content is more than 98.5%.
Embodiment 3:
In there-necked flask, add 120 amino-3 cyanopyridines of gram 2-and 140 milliliters of ethanol, add 220 gram triethylamines under stirring; Slowly add the cyclopropane bromide of 123 grams again, added afterreaction 24 hours, HPLC analyzes up to reacting completely; The pressure reducing and steaming solvent adds 300 ml waters; Be cooled to the 0-5 degree, filter and obtain 150 gram products, content is more than 98.5%.
Embodiment 4:
In there-necked flask, add 135 gram 2-(cyclopropyl amino)-3-cyanopyridine and 300 milliliters of ethanol, stir the 350 gram potassium hydroxide solutions of adding down; Heat to backflow, HPLC analyzes up to reacting completely, and the pressure reducing and steaming solvent adds 300 ml waters; Be cooled to the 0-5 degree, add hydrochloric acid and transfer PH, filter to 2-3; Water washing obtains 135 gram products, and content is more than 99%.

Claims (6)

1. the preparation method of an anti-AIDS drug nevirapine key intermediate 2-(cyclopropyl amino)-3-pyridine carboxylic acid is characterized in that: be made up of following 2 steps reaction:
Amino 3-cyanopyridine of the first step: 2-and halo Trimetylene react in the presence of solvent and acid binding agent and obtain 2-(cyclopropyl amino)-3-cyanopyridine;
Second step: the hydrolysis under alkaline condition of 2-(cyclopropyl amino)-3-cyanopyridine obtains nevirapine key intermediate 2-(cyclopropyl amino)-3-pyridine carboxylic acid
be X=Cl or Br wherein.
2. the preparation method of a kind of anti-AIDS drug nevirapine key intermediate 2-according to claim 1 (cyclopropyl amino)-3-pyridine carboxylic acid; It is characterized in that: in the first step; Said halo Trimetylene is meant chloro Trimetylene or cyclopropane bromide, and said solvent is meant the mixing solutions of water, alcohol or water and alcohol.
3. the preparation method of a kind of anti-AIDS drug nevirapine key intermediate 2-according to claim 2 (cyclopropyl amino)-3-pyridine carboxylic acid is characterized in that: said alcohol is that carbon 1 is to carbon 6 alcohol, terepthaloyl moietie, propandiols material.
4. according to the preparation method of the said a kind of anti-AIDS drug nevirapine key intermediate 2-of claim 1 (cyclopropyl amino)-3-pyridine carboxylic acid; It is characterized in that: in the first step, said acid binding agent is meant triethylamine, diethylamine, ethamine class amine salt and salt of wormwood, yellow soda ash class carbonate.
5. the preparation method of a kind of anti-AIDS drug nevirapine key intermediate 2-according to claim 1 (cyclopropyl amino)-3-pyridine carboxylic acid is characterized in that: the temperature of reaction of the first step is 10~100 degree; The amino 3-cyanopyridine of 2-: halo Trimetylene: acid binding agent: solvent (mol ratio)=1:0.2~5:0.2~5:1~100.
6. the preparation method of a kind of anti-AIDS drug nevirapine key intermediate 2-according to claim 1 (cyclopropyl amino)-3-pyridine carboxylic acid is characterized in that: hydrolysis is under the condition of alkaline condition sodium hydroxide or Pottasium Hydroxide existence, to react.
CN201110180511A 2011-06-30 2011-06-30 Method for preparing key intermediate 2-(cyclopropylamido)-3-pyridine formic acid of anti-aids medicament Nevirapine Pending CN102321015A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201110180511A CN102321015A (en) 2011-06-30 2011-06-30 Method for preparing key intermediate 2-(cyclopropylamido)-3-pyridine formic acid of anti-aids medicament Nevirapine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201110180511A CN102321015A (en) 2011-06-30 2011-06-30 Method for preparing key intermediate 2-(cyclopropylamido)-3-pyridine formic acid of anti-aids medicament Nevirapine

Publications (1)

Publication Number Publication Date
CN102321015A true CN102321015A (en) 2012-01-18

Family

ID=45448885

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201110180511A Pending CN102321015A (en) 2011-06-30 2011-06-30 Method for preparing key intermediate 2-(cyclopropylamido)-3-pyridine formic acid of anti-aids medicament Nevirapine

Country Status (1)

Country Link
CN (1) CN102321015A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1653065A (en) * 2002-06-28 2005-08-10 贝林格尔英格海姆化学公司 Improved method for making nevirapine
CN101405002A (en) * 2005-12-29 2009-04-08 詹森药业有限公司 Prokineticin 2 receptor antagonists
CN101448836A (en) * 2006-05-23 2009-06-03 霍夫曼-拉罗奇有限公司 Pyridopyrimidinone derivatives
CN101585836A (en) * 2008-05-25 2009-11-25 浙江华海药业股份有限公司 Novel method for preparing Nevirapine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1653065A (en) * 2002-06-28 2005-08-10 贝林格尔英格海姆化学公司 Improved method for making nevirapine
CN1280293C (en) * 2002-06-28 2006-10-18 贝林格尔英格海姆化学公司 Improved method for making nevirapine
CN101405002A (en) * 2005-12-29 2009-04-08 詹森药业有限公司 Prokineticin 2 receptor antagonists
CN101448836A (en) * 2006-05-23 2009-06-03 霍夫曼-拉罗奇有限公司 Pyridopyrimidinone derivatives
CN101585836A (en) * 2008-05-25 2009-11-25 浙江华海药业股份有限公司 Novel method for preparing Nevirapine

Similar Documents

Publication Publication Date Title
CN103304512A (en) Preparation method for febuxostat
CN104725303A (en) Synthetic method of 2-chloro-N-(4'-chlorodiphenyl-2-yl) nicotinamide
CN102336686A (en) Preparation method of 2-(7-methoxy-1-naphthyl) acetonitrile
CN105330598A (en) Preparing method for pirfenidone
CN109081810A (en) The synthetic method of 1- methyl-3-((methylamino) methyl)-1H- pyrazoles-5- nitrile
CN103922965B (en) A kind of synthetic method of 4-methoxyl group-2-methylbenzeneacetonitrile
CN105566237A (en) Preparing method of triazole thioglycolic acid compound for curing metabolic arthritis
CN105541714A (en) Preparation methods of papaverine and papaverine hydrochloride
CN109293513A (en) A kind of preparation method of sitafloxacin intermediate
CN107118215B (en) A kind of preparation method for treating breast cancer medicines Rui Boxini intermediate
CN101654419A (en) Preparation method of fluvoxamine maleate
CN100537552C (en) Method for preparing Repaglinide
CN103333117B (en) The preparation method of a kind of 4 [(the chloro-2-pyrimidyl of 4-) is amino] cyanophenyl
CN111423366A (en) Preparation method of pirfenidone
CN101698664B (en) Preparation method of pharmaceutical intermediate 2-amine methylpyrazine hydrochloride
CN100999502B (en) Process of selectively synthesizing 5-methyl pyrazine-2-carboxylic acid using 2,5-dimethyl pyrazine
CN102321015A (en) Method for preparing key intermediate 2-(cyclopropylamido)-3-pyridine formic acid of anti-aids medicament Nevirapine
CN111253241B (en) 2,4,5-trifluoro-3-methoxybenzoyl chloride and preparation method of intermediate thereof
CN101602713B (en) Novel method for synthesizing 2-chloronicotinic acid
CN104326988B (en) A kind of synthetic method of 2,4-dichloro-5-methoxy pyrimidines
CN104292133B (en) The synthetic method of a kind of cancer therapy drug Vorinostat
CN107011288A (en) A kind of preparation method of aripiprazole intermediate 1 (2,3 dichlorophenyl) piperazine hydrochloride
CN102399191B (en) Method for synthesizing analgin
CN102976929A (en) Method for synthesizing (4-chloro-2-phenoxy phenyl)-acetic acid
CN111675663A (en) Preparation method of Favipiravir

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120118